Although the diagnostic power of serum BSP levels (AUCBSP: 0.665) for the differentiation of pancreatic cancer patients and healthy controls was inferior to tumor markers such as CA19-9 and CEA (AUCCA19-9: 0.908, AUCCEA: 0.786, Fig. 1b), the combinational use of BSP and CA19-9 was superior to each serum marker alone (AUCBSP/CA19-9: 0.931, Fig. 1c). This evidence concerns the gene IBSP and familial pancreatic carcinoma.